Research programme: cancer therapeutics - BeiGene

Drug Profile

Research programme: cancer therapeutics - BeiGene

Alternative Names: BGB-108; BGB-A425; Brodomain containing protein 4 inhibitors - BeiGene; EGFR T790 mutation inhibitors - BeiGene; iOnc monoclonal antibody - BeiGene; iONC small molecule therapeutic - BeiGene; KRAS protein inhibitors - BeiGene; PD-1 monoclonal antibody - BeiGene; PD-L1 monoclonal antibody - BeiGene; Tim-3 antibody

Latest Information Update: 18 Nov 2014

Price : $50

At a glance

  • Originator BeiGene
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; CD274 antigen modulators; Epidermal growth factor inhibitors; HAVCR2 protein modulators; Immunomodulators; KRAS protein inhibitors; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Nov 2014 Preclinical trials in Cancer in China (Parenteral)
  • 14 Nov 2014 Preclinical trials in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top